Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.
Bracke A, De Hert E, De Bruyn M, Claesen K, Vliegen G, Vujkovic A, van Petersen L, De Winter FHR, Hotterbeekx A, Brosius I, Theunissen C, Van Ierssel S, van Frankenhuijsen M, Vlieghe E, Vercauteren K, Van der Veken P, Hendriks D, Kumar-Singh S, De Meester I. Bracke A, et al. Among authors: van frankenhuijsen m. Clin Chim Acta. 2022 Jun 1;531:4-11. doi: 10.1016/j.cca.2022.03.005. Epub 2022 Mar 10. Clin Chim Acta. 2022. PMID: 35283094 Free PMC article.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.
Claesen K, Sim Y, Bracke A, De Bruyn M, De Hert E, Vliegen G, Hotterbeekx A, Vujkovic A, van Petersen L, De Winter FHR, Brosius I, Theunissen C, van Ierssel S, van Frankenhuijsen M, Vlieghe E, Vercauteren K, Kumar-Singh S, De Meester I, Hendriks D. Claesen K, et al. Among authors: van frankenhuijsen m. J Clin Med. 2022 Mar 9;11(6):1494. doi: 10.3390/jcm11061494. J Clin Med. 2022. PMID: 35329820 Free PMC article.
Mpox screening in high-risk populations finds no asymptomatic cases.
Van Dijck C, De Baetselier I, Kenyon C, Liesenborghs L; ITM Monkeypox Study Group; Vercauteren K, Van Esbroeck M. Van Dijck C, et al. Lancet Microbe. 2023 Mar;4(3):e132-e133. doi: 10.1016/S2666-5247(22)00357-3. Epub 2022 Dec 9. Lancet Microbe. 2023. PMID: 36509096 Free PMC article. No abstract available.
Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak.
Hens M, Brosius I, Berens-Riha N, Coppens J, Van Gestel L, Rutgers J, Kenyon C, Soentjens P, van Henten S, Bracke S, Vanbaelen T, Vandenhoven L, Bottieau E, Vercauteren K, Van Esbroeck M, Liesenborghs L, Van Dijck C; ITM mpox study groupc; ITM mpox study group. Hens M, et al. New Microbes New Infect. 2023 Feb 9;52:101093. doi: 10.1016/j.nmni.2023.101093. eCollection 2023 Mar. New Microbes New Infect. 2023. PMID: 36874154 Free PMC article.
Leveraging T-cell receptor - epitope recognition models to disentangle unique and cross-reactive T-cell response to SARS-CoV-2 during COVID-19 progression/resolution.
Postovskaya A, Vujkovic A, de Block T, van Petersen L, van Frankenhuijsen M, Brosius I, Bottieau E, Van Dijck C, Theunissen C, van Ierssel SH, Vlieghe E, Bartholomeus E, Mullan K, Adriaensen W, Vanham G, Ogunjimi B, Laukens K, Vercauteren K, Meysman P. Postovskaya A, et al. Among authors: van frankenhuijsen m. Front Immunol. 2023 May 31;14:1130876. doi: 10.3389/fimmu.2023.1130876. eCollection 2023. Front Immunol. 2023. PMID: 37325653 Free PMC article.
Diagnosing Viral Infections Through T-Cell Receptor Sequencing of Activated CD8+ T Cells.
Vujkovic A, Ha M, de Block T, van Petersen L, Brosius I, Theunissen C, van Ierssel SH, Bartholomeus E, Adriaensen W, Vanham G, Elias G, Van Damme P, Van Tendeloo V, Beutels P, van Frankenhuijsen M, Vlieghe E, Ogunjimi B, Laukens K, Meysman P, Vercauteren K. Vujkovic A, et al. Among authors: van frankenhuijsen m. J Infect Dis. 2024 Feb 14;229(2):507-516. doi: 10.1093/infdis/jiad430. J Infect Dis. 2024. PMID: 37787611 Free PMC article.
Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.
De Wit S, Florence E, Vandekerkhove L, Goffard JC, Vandercam B, Van Wijngaerden E, Moutschen M, Demeester R, Lacor P, Delforge M, van Frankenhuijsen M, Lacante P. De Wit S, et al. Among authors: van wijngaerden e, van frankenhuijsen m. Acta Clin Belg. 2019 Jun;74(3):143-150. doi: 10.1080/17843286.2018.1462753. Epub 2018 May 2. Acta Clin Belg. 2019. PMID: 29718781
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2021 Aug 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. J Antimicrob Chemother. 2021. PMID: 34120186 Clinical Trial.
16 results